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ardiac Computed
omographic Angiography
hat’s the Prognosis?*
aniel B. Mark, MD, MPH, David F. Kong, MD
urham, North Carolina
omputed tomography (CT) has been a source of recurring
ontroversy since its introduction into medical practice in
973 (1). In those early years, pictures revealing unprece-
ented structural detail of living brains and bodies, obtained
ithout invasive procedures, were sufficiently compelling to
nspire enthusiastic incorporation into clinical practice. The
otential economic effects of such enthusiasm, however,
rompted regulators in many states to attempt to limit
issemination of these machines, often without success.
oncurrently, these developments stimulated health services
esearchers to consider what evidence was needed to declare
T (or any other imaging technology) validated for routine
linical practice. In 1982, Fryback and Thornbury (2)
resented a 6-level hierarchical model of diagnostic test
fficacy that continues to shape the approach to test evalu-
tion today (3). In this model, a diagnostic test must first
rove it functions as intended at the technical level (level 1).
his is followed by evaluation of its diagnostic accuracy
level 2), its effects on diagnostic thinking (level 3), its effects
n treatment selection (level 4), its effects on patient
utcomes (level 5), and finally its effects on societal out-
omes, including cost-effectiveness (level 6).
See page 1017
More recently, CT has returned to the center of contro-
ersy, this time focusing on the use of multidetector CT
achines to image coronary arteries (4). Once again,
larmed payers have asserted that use of this technology
xtends far beyond the available evidence of its value. In
ecember 2007, the Centers for Medicare and Medicaid
ervices (CMS) proposed a draft national coverage decision
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From the Duke Clinical Research Institute and the Division of Cardiology and
epartment of Medicine, Duke University Medical Center, Durham, North Caro-
ina. Dr. Mark has consulted for Aventis, AstraZeneca, Medtronic, and Novartis; andw
as received research grants from Eli Lilly and Company, Proctor & Gamble, Pfizer,
edtronic, Alexion Pharmaceuticals, Medicure, Innocoll, and St. Jude’s.hat restricted payment for this test to use in 2 select
opulations (intermediate risk symptomatic stable patients,
nd unstable angina patients) and required participation in
n approved research study as a condition of payment (5). A
restorm of objections forced CMS to retreat from its plan.
n a March 2008 decision memorandum, CMS specifically
eferenced the evidence hierarchy model of Fryback and
hornbury as justification that evidence pertaining to pa-
ient outcomes (level 3 or higher) would be required to
upport a national coverage decision (6). Opponents of the
raft Medicare decision countered that most diagnostic
tudies in current use are not supported by such evidence.
egulators and clinicians are now actively searching for
pportunities to justify potential uses of coronary computed
omographic angiography (CTA) in the context of increas-
ngly rigorous standards for evidence-based practice.
Notably, the diagnostic imaging evidence hierarchy
odel makes no mention of prognostic data. This apparent
versight reflects the scarcity of such data when the model
as initially proposed (D.G. Fryback, personal communi-
ation, October 2009). Diagnostic accuracy is most often
ssessed using a convenience sample of patients who un-
ergo both the new test of interest and the reference
tandard test. Small, single-institution studies of this sort
onstitute the bulk of the level 2 evidence about coronary
TA to date (7). Prognostic data, in contrast, require years
f careful follow-up in much larger cohorts, and significant
osses to follow-up can irreparably damage the value of the
ork (8). Proof that a test provides independent prognostic
ata does not necessarily prove that its use improves patient
utcomes. However, it does provide a signal suggesting that
uch effects may be possible.
In this issue of the Journal, Chow et al. (9) present a large,
arefully done, single-institution study on the prognostic
alue of 64-channel cardiac CTA. Over a 2-year period,
hese investigators prospectively enrolled 2,076 subjects
eferred for cardiac CTA into a registry and followed them
or an average of 16 months. This study is noteworthy
ecause previous prognostic studies either used obsolete CT
achines or involved much smaller cohorts with fewer
utcome events (and therefore less statistical power) (8,10).
he primary finding that coronary artery disease (CAD)
everity assessed as either obstructive disease (50% diam-
ter stenosis) or severe disease (50% left main, 3-vessel
isease, or 2-vessel disease with proximal left anterior
escending artery disease) added significant prognostic in-
ormation to both baseline clinical data and left ventricular
jection fraction bolsters the evidence base for cardiac CTA
sing contemporary equipment and procedures. These gen-
ral relationships have been amply demonstrated by decades
f invasive angiography. Therefore, it is not surprising that
TA adds some incremental prognostic value to basic
linical risk data, similar to what had been previously seen
ith invasive catheter-based methods.
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Coronary CTA: What’s the Prognosis? March 9, 2010:1029–31Yet, “similar” is not necessarily “equivalent.” One of the
uestions raised in the 2008 CMS review was whether CTA
ould replace invasive diagnostic angiography in patients
ho currently undergo catheterization. Chow et al. (9) did
ot directly determine whether prognostic estimates from
TA are interchangeable with invasive angiography because
his would have required all patients to undergo both tests
uring their baseline assessment, an enormous challenge for
cohort of this size. On the other hand, many studies have
hown that the likelihood of cardiovascular death is primar-
ly driven by events in the patients with the most severe
AD. Only 21% of the cohort assembled by Chow et al. (9)
ad coronary artery diameter narrowing of 70% in 1
ajor coronary artery. Thus, most of the study patients were
ot likely to contribute any coronary events in follow-up.
he weakness of cardiac CTA in CAD diagnosis lies in its
endency to overestimate disease severity relative to invasive
ngiography (7). This type of misclassification decreases the
eliability of prognostic estimates relative to the correspond-
ng findings from invasive angiography.
Anatomic misclassifications are amplified by the fact that
he stenosis on any angiogram is a surrogate for the effect of
he lesion on coronary blood flow. Although the paramount
istinction between structure and function has been recog-
ized for more than 25 years, the visual impression of the
ngiogram is so powerfully seductive that an obsession with
coronary luminology” still dominates modern cardiovascu-
ar practice (11). Unfortunately, sole reliance on angio-
raphic data for treatment decisions leads to substantial
veruse of percutaneous revascularization compared with
ombined structural and functional information (12,13).
lthough preliminary data suggest that special dual-energy
T techniques can also measure myocardial perfusion (14),
ardiac CT in its most common incarnation is very much
nother anatomic tool.
One distinguishing feature of cardiac CTA is its ability to
dentify normal and abnormal features of the arterial wall,
ffering the possibility of a novel perspective into risk
tratification for future coronary plaque–related clinical
vents. Chow et al. (9) used a total plaque score, calculated
s the number of coronary segments with a visible plaque of
ny degree of stenosis, to estimate the burden of CAD. In
ultivariable analyses, this score added independent prog-
ostic information to both a 4-level CAD severity measure
nd ejection fraction. In an earlier prognostic study of
6-channel cardiac CTA in 1,127 symptomatic patients,
in et al. (10) found that a similar “segment involvement
core” was an independent prognostic factor in multivariable
nalyses (adjusting only for age, dyslipidemia, and family
istory). Although the plaque scoring systems are intrigu-
ng, their prognostic advantage over a thorough accounting
f CAD severity remains equivocal. Resolving the concep-
ual and statistical properties of these different measures of
AD severity and distribution will require samples witharger numbers of outcome events.Even the best prognostic data imaginable will not reveal
ow a test alters physician thinking (level 3) and patient
anagement (level 4). Chow et al. (9) report that CAD
everity data altered the 10-year risk predictions for approx-
mately 20% of patients, which addresses how these data
ight alter clinician thinking, but not whether it actually
hanges decision making. Indeed, more precise test results
ill not change patient health outcomes (level 5) unless they
nfluence physician or patient behavior. Very few modern
iagnostic tests have evidence directly connecting their
ndings with changes in patient outcomes. Ongoing com-
arative effectiveness initiatives seek to overcome this gap.
n October 2009, the National Heart, Lung, and Blood
nstitute funded PROMISE (PROspective Multicenter
maging Study for Evaluation of Chest Pain), a randomized
rial of initial 64-channel cardiac CTA versus initial
unctional stress testing in 10,000 low- to intermediate-risk
atients. Designed as a real-world pragmatic trial, the
ROMISE trial will test whether an initial anatomic
trategy with cardiac CTA will reduce a composite clinical
utcome event (including death and myocardial infarction)
y 20% compared with an initial functional testing strategy
ver an average follow-up of 2.5 years (15).
To improve clinical outcomes, a cardiac CTA-based
trategy must provide clinicians with actionable information
o direct prognosis-modifying treatments efficiently and
ccurately. The data from Chow et al. (9) together with
ngoing investigations should help us to determine whether
he tomographic noninvasive denomination of luminology
ffers a “PROMISEing” prognosis or simply another op-
ortunity to recite the catechisms of the past.
eprint requests and correspondence: Dr. Daniel B. Mark,
uke Clinical Research Institute, P.O. Box 17969, Durham,
orth Carolina 27715. E-mail: daniel.mark@duke.edu.
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